Print this page
colorectal
-
Optimizing Colorectal Cancer Screening Among Patients with Diabetes in Safety-Net Primary Care Settings: Targeting Implementation Approaches.
Protocol: 002056Applicable Disease Sites: Colon
-
Optimizing Colorectal Cancer Screening Among Patients with Diabetes in Safety-Net Primary Care Settings: Targeting Implementation Approaches.
Protocol: 002056Applicable Disease Sites: Colon
-
Video Education with Result Dependent dIsclosure (VERDI)
Protocol: 042207Principal Investigator:
- Deborah L Toppmeyer
Applicable Disease Sites: Breast
Colon
Kidney
Melanoma, Skin
Ovary
Pancreas
Prostate
Soft Tissue -
Video Education with Result Dependent dIsclosure (VERDI)
Protocol: 042207Principal Investigator:
- Deborah L Toppmeyer
Applicable Disease Sites: Breast
Colon
Kidney
Melanoma, Skin
Ovary
Pancreas
Prostate
Soft Tissue -
A First-in-Human Study of Mutant-Selective PI3K Alpha Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer.
Protocol: 042402Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
A First-in-Human Study of Mutant-Selective PI3K Alpha Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer.
Protocol: 042402Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of RO7589831 in Participants With Advanced Solid Tumors Harboring Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR).
Protocol: 052407Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of RO7589831 in Participants With Advanced Solid Tumors Harboring Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR).
Protocol: 052407Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in combination with Cetuximab, in Participants with KRAS G12C-Mutant, Advanced Solid Tumors.
Protocol: 052508Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
PERitoneal Carcinomatosis LEveraging ctDNA guided treatment Study in GI Cancer (PERICLES Study).
Protocol: 072013Principal Investigator:
- Henry Richard Alexander
Applicable Disease Sites: Colon
Esophagus
Ill-Defined Sites
Other Digestive Organ
Pancreas
Rectum
Small Intestine
Stomach
Unknown Sites -
A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in combination with Cetuximab, in Participants with KRAS G12C-Mutant, Advanced Solid Tumors.
Protocol: 052508Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
PERitoneal Carcinomatosis LEveraging ctDNA guided treatment Study in GI Cancer (PERICLES Study).
Protocol: 072013Principal Investigator:
- Henry Richard Alexander
Applicable Disease Sites: Colon
Esophagus
Ill-Defined Sites
Other Digestive Organ
Pancreas
Rectum
Small Intestine
Stomach
Unknown Sites -
Preoperative ChemoRadiation and FOLFOXIRI To Escalate Complete Response for Rectal Cancer.
Protocol: 072202Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Rectum -
Colon Adjuvant Chemotherapy Based On Evaluation of Residual Disease.
Protocol: 072207Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Colon -
Sequential Combined TAS-102 and Oxaliplatin Alternating with TAS-102 and Irinotecan (Sequential TASOXIRI) with Bevacizumab for Late-Line Metastatic Colorectal Cancer.
Protocol: 072303Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Colon -
Preoperative ChemoRadiation and FOLFOXIRI To Escalate Complete Response for Rectal Cancer.
Protocol: 072202Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Rectum